Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
JNCI Cancer Spectrum|April 25, 2020
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 PatientsNicole G Chau, Clement Ma, Kristina Danga, et al.
The American Journal of Surgical Pathology|April 14, 2009
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibodyHerbert Haack, Laura A Johnson, Christopher J Fry, et al.
The American Journal of Surgical Pathology|April 24, 2018
Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated CarcinomasJeffrey K Mito, Justin A Bishop, Peter M Sadow, et al.
Histopathology|December 8, 2016
NUT midline carcinoma of the larynx: an international series and review of the literatureHenrik Hellquist, Christopher A French, Justin A Bishop, et al.
Thyroid : Official Journal of the American Thyroid Association|July 27, 2016
Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective AnalysisKyle C Strickland, Marina Vivero, Vickie Y Jo, et al.
Molecular Cancer Research : MCR|July 21, 2021
Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and TreatmentHitoshi Shiota, Artyom A Alekseyenko, Zhipeng A Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Midline carcinoma of children and young adults with NUT rearrangementChristopher A French, Jeffery L Kutok, William C Faquin, et al.
Cancer|August 11, 2016
Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neckNicole G Chau, Shelley Hurwitz, Chelsey M Mitchell, et al.
Molecular Cancer Therapeutics|May 7, 2020
Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734Chevaun D Morrison-Smith, Tatiana M Knox, Ivona Filic, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Pageof 9